NEWS30 May 2022
Surrey Research Park company ANGLE Plc are welcoming a new era of personalised cancer care, having achieved the world’s first US Food and Drug Administration (FDA) approval for the capture and harvest of cancer cells from metastatic breast cancer patients.
The Parsortix® PC1 Clinical System is set to revolutionise the future of cancer treatment by filtering cancer cells from blood samples, allowing repeat biopsies and precise detection of a cancer’s type and stage at any point in a patient’s journey. This removes complexity and supports doctors in delivering bespoke treatment plans.
The Company believes intact living cancer cells are the “best sample” for analysis, adding vital additional information to the current industry approach of analysing fragments of dead cancer cells (known as ctDNA).
ANGLE Founder and Chief Executive, Andrew Newland, commented:
“We are absolutely delighted that FDA has cleared the Parsortix system and believe this heralds a new era for personalised cancer care. This ground-breaking first ever FDA product clearance in metastatic breast cancer provides the platform for ANGLE to work with our collaborators and customers to support further FDA submissions and the establishment of numerous specific clinical uses across different cancer types. By making the Parsortix system widely available, we intend to support the entire industry in its adoption of liquid biopsy solutions for repeat non-invasive diagnostics for personalised cancer care. Large-scale medtech and pharma companies now have an FDA cleared platform on which to develop new medical solutions.”
FDA product clearance, which is the global gold standard for medical devices, gives ANGLE first mover advantage for intact cell analysis in the global liquid biopsy market, which it is estimated will grow to over US$100 billion per annum in the United States alone.
ANGLE Plc was founded in 1994 and has been based at Surrey Research Park ever since, expanding into new premises to meet their changing business needs. We are delighted to be able to both witness, and be part of, their ongoing growth journey.
For more information visit www.angleplc.com